Effectiveness of the Zenicog® Cognitive Rehabilitation Program for Older Adults with Mild Cognitive Impairment: A Randomized Controlled Trial/A pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008968

Enrollment

Registered

2023-11-21

Start date

2023-11-22

Completion date

Unknown

Last updated

2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : 1. During the intervention period, participants will perform 24 sessions of the Zenicog® program installed on a tablet PC within their home environment, over the course of 5weeks (one session

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The research targets older adults, with an age restriction of 65 years and older. 2) Participants will be selected as older adults with cognitive impairment, based on a criterion of MMSE (Mini-Mental State Examination) scores within the range of 18 to 26 points.

Exclusion criteria

Exclusion criteria: Patients with limitations in using computerized devices due to visual, auditory, or motor impairments will be excluded. Individuals with a significant level of digital illiteracy, making it difficult to operate smart devices, will be excluded. Subjects with severe mental disorders (such as schizophrenia, bipolar disorder, etc.) or major depressive disorders (severe depression, secondary depression, etc.) that may impair cognitive assessment will be excluded. Individuals who are taking medications that could affect cognitive function will be excluded. 3-1) Users of dementia treatment drugs (acetylcholinesterase inhibitors like donepezil, galantamine, rivastigmine, etc.) will be excluded. 3-2) Central nervous system drugs: Antipsychotic medications, antidepressants, alcohol-related drugs (medications for alcohol addiction treatment), sedatives (tranquilizers, sedatives, benzodiazepine drugs, etc.). 3-3) Opioid drugs (e.g., oxycodone) will also result in exclusion.

Design outcomes

Primary

Measure	Time frame
Cognitive Function Indicator: Comprehensive Cognitive Indicator (K-MMSE2);Attention and Concentration (Trail making test A, Word-color test);Working Memory(Digit span, Visual span test);Executive Function (Trail Making Test B, Card Sorting Test);Psychological outcome measures: 1) Quality of Life Measure (EQ-5D-5L) 2) Self-esteem (Self Efficacy Scale) 3) Depression (Korean version of Center for Epidemiological Studies-Depression Scale, K-CES-D);Activities of Daily Living (ADL) measure: Seoul-Instrumental Activities of Daily Living (S-IADL);Electromyography Biomarkers	—

Measure

Time frame

Cognitive Function Indicator: Comprehensive Cognitive Indicator (K-MMSE2);Attention and Concentration (Trail making test A, Word-color test);Working Memory(Digit span, Visual span test);Executive Function (Trail Making Test B, Card Sorting Test);Psychological outcome measures: 1) Quality of Life Measure (EQ-5D-5L) 2) Self-esteem (Self Efficacy Scale) 3) Depression (Korean version of Center for Epidemiological Studies-Depression Scale, K-CES-D);Activities of Daily Living (ADL) measure: Seoul-Instrumental Activities of Daily Living (S-IADL);Electromyography Biomarkers

—

Secondary

Measure	Time frame
Psychological outcome measures: 1) Quality of Life Measure (EQ-5D-5L) 2) Self-esteem (Self Efficacy Scale) 3) Depression (Korean version of Center for Epidemiological Studies-Depression Scale, K-CES-D);Activities of Daily Living (ADL) measure: Seoul-Instrumental Activities of Daily Living (S-IADL);Usability Analysis: Usability Test (Development Questionnaire);Electromyography Biomarkers;Cognitive Function Indicator: Comprehensive Cognitive Indicator (K-MMSE2);Attention and Concentration (Trail making test A, Word-color test);Working Memory(Digit span, Visual span test);Executive Function (Trail Making Test B, Card Sorting Test)	—

Measure

Time frame

Psychological outcome measures: 1) Quality of Life Measure (EQ-5D-5L) 2) Self-esteem (Self Efficacy Scale) 3) Depression (Korean version of Center for Epidemiological Studies-Depression Scale, K-CES-D);Activities of Daily Living (ADL) measure: Seoul-Instrumental Activities of Daily Living (S-IADL);Usability Analysis: Usability Test (Development Questionnaire);Electromyography Biomarkers;Cognitive Function Indicator: Comprehensive Cognitive Indicator (K-MMSE2);Attention and Concentration (Trail making test A, Word-color test);Working Memory(Digit span, Visual span test);Executive Function (Trail Making Test B, Card Sorting Test)

—

Countries

Korea, Republic of

Contacts

Public Contacttaeksoo jeong

Catholic Kwandong University International St.Mary's Hospital

jeongtaeksoo8@gmail.com+82-32-290-3117

Outcome results